Last reviewed · How we verify
NCT03499444
A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Phase 1 trial testing Rucaparib in Advanced Solid Tumor in 29 participants. Completed in 13 April 2022.
18 June 2019
Quick facts
| Lead sponsor | pharmaand GmbH |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 29 |
| Start date | 6 February 2018 |
| Primary completion | 18 June 2019 |
| Estimated completion | 13 April 2022 |
| Sites | 3 locations across Japan |
Drugs / interventions tested
- Rucaparib (RUCAPARIB) — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
pharmaand GmbH — full company profile →
Who can join
20 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1 open-label, dose-escalation, safety and pharmacokinetic study of rucaparib administered twice daily (BID) to Japanese patients with a solid tumor who have failed previous standard treatment for their cancer. A recommended dose of rucaparib for Japanese patients will be determined in a dose-escalation portion and then further evaluated in a dose-expansion portion of the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M, Beltman J, Giordano H, Harding TC, et al · · 2022 · cited 8× · PMID 36107395 · DOI 10.1007/s40262-022-01157-8
Verify or expand the search:
- PubMed search for NCT03499444
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Rucaparib
Trials testing the same drug.
- NCT04676334 — CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib · Phase 3 · completed
- NCT03462212 — Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, · Phase 1, PHASE2 · unknown
- NCT04624178 — A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma · Phase 2 · active not recruiting
- NCT04826198 — Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Pa · Phase 1, PHASE2 · terminated
- NCT04539327 — Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study · completed
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Other pharmaand GmbH trials
Trials by the same sponsor.
- NCT04676334 — CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib · Phase 3 · completed
- NCT04171700 — A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes · Phase 2 · terminated
- NCT04179396 — Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) · Phase 1 · completed
- NCT04150289 — A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat · completed
- NCT03824704 — A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03499444 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by pharmaand GmbH
- Last refreshed: 9 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03499444.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing